Propriedade e atividade de insiders de ADMA Biologics, Inc. (ADMA): operações de insiders, negociações do Senado e da Câmara dos EUA e ações em circulação. Acompanhe como executivos e políticos negociam a ação.
Preço
| Preço | $8.90 |
| Capitalização | $2.1B |
| Bolsa | NASDAQ |
| País | US |
Operações Recentes de Insiders
| Data | Insider | Tipo | Ações | Valor |
|---|---|---|---|---|
| 2026-07-24 | Kestenberg-Messina Kaitlin M. | F-InKind | 3,177 | $27K |
| 2026-07-16 | Kohler Terry | A-Award | 85,130 | |
| 2026-07-16 | Kohler Terry | A-Award | 136,363 | $1.2M |
| 2026-05-27 | Grossman Jerrold B | P-Purchase | 6,400 | $51K |
| 2026-05-12 | Grossman Jerrold B | P-Purchase | 12,500 | $100K |
| 2026-05-11 | Grossman Jerrold B | P-Purchase | 12,500 | $100K |
| 2026-04-01 | Kestenberg-Messina Kaitlin M. | F-InKind | 20,362 | $185K |
| 2026-03-13 | Guiheen Lawrence P. | M-Exempt | 30,000 | $110K |
| 2026-03-17 | Guiheen Lawrence P. | G-Gift | 30,000 | |
| 2026-03-17 | Guiheen Lawrence P. | G-Gift | 30,000 |
Balanço (10 anos)
| Ano | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caixa e Equivalentes | $9.9M | $43.1M | $22.8M | $26.8M | $55.9M | $51.1M | $86.5M | $51.4M | $103.1M | $87.6M |
| Investimentos de Curto Prazo | $5.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Contas a Receber | $1.0M | $3.9M | $1.4M | $3.5M | $13.2M | $28.6M | $15.5M | $27.4M | $50.0M | $158.4M |
| Estoque | $5.0M | $12.6M | $18.6M | $53.1M | $81.5M | $124.7M | $163.3M | $172.9M | $170.2M | $206.5M |
| Ativos Circulantes | $21.7M | $63.2M | $44.5M | $85.8M | $153.7M | $208.7M | $270.4M | $257.0M | $331.4M | $466.5M |
| Imobilizado | $2.0M | $30.5M | $30.1M | $33.0M | $45.9M | $58.2M | $68.7M | $63.5M | $63.3M | $71.7M |
| Ágio | 0 | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M |
| Ativos Intangíveis | 0 | $4.8M | $4.0M | $3.2M | $2.4M | $1.7M | $1.0M | $499000 | $460000 | $632000 |
| Ativos Totais | $23.7M | $108.0M | $88.9M | $127.1M | $207.7M | $276.3M | $348.5M | $329.2M | $488.7M | $624.2M |
| Contas a Pagar | $2.6M | $5.9M | $5.9M | $9.2M | $11.1M | $12.4M | $13.2M | $15.7M | $20.2M | $22.5M |
| Dívida de Curto Prazo | $6.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.8M |
| Passivos Circulantes | $11.2M | $9.4M | $9.6M | $14.0M | $19.9M | $30.4M | $39.3M | $49.8M | $55.5M | $69.5M |
| Dívida de Longo Prazo | $14.1M | $43.0M | $44.1M | $83.2M | $93.0M | $94.9M | $142.8M | $130.6M | $72.3M | $69.3M |
| Passivos Totais | $28.1M | $67.7M | $69.1M | $100.9M | $119.4M | $135.1M | $196.5M | $194.0M | $139.7M | $146.9M |
| Reservas | -$106.9M | -$150.7M | -$216.4M | -$264.7M | -$340.5M | -$412.1M | -$478.0M | -$506.3M | -$308.6M | -$161.7M |
| Patrimônio Líquido | -$4.5M | $40.3M | $19.8M | $26.2M | $88.2M | $141.2M | $152.0M | $135.2M | $349.0M | $477.3M |
| Dívida Total | $20.3M | $43.0M | $44.2M | $84.7M | $97.7M | $102.9M | $154.4M | $141.4M | $82.1M | $79.9M |
| Dívida Líquida | $5.0M | -$136720 | $21.5M | $58.0M | $41.7M | $51.8M | $67.9M | $90.1M | -$21.0M | -$7.7M |
| Capital de Giro | $10.4M | $53.7M | $34.9M | $71.8M | $133.8M | $178.4M | $231.1M | $207.2M | $275.9M | $397.0M |
Saúde financeira
| Dívida / Patrimônio | 0.50 |
| Liquidez corrente | 6.97 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 19.98 |
Rentabilidade
| Retorno sobre patrimônio | 30.78% |
| Retorno sobre capital investido | 27.57% |
| Retorno sobre ativos | 23.54% |
| Margem bruta | 64.71% |
| Margem operacional | 42.26% |
| Margem líquida | 32.98% |
Empresas relacionadas: ACAD · BLTE · CRNX · DYN · LGND · MIRM · PRAX
Explorar setor: Healthcare · Biotechnology
Mais seções de ADMA: Resumo · Financeiros · Avaliação · Estatísticas · Estimativas · Técnico · Notícias · Eventos
Descubra mais: Radar — sinais de ações subvalorizadas · Academia de Investimento — aprenda a analisar ações